ECSS
MDGL icon

Eurizon Capital SGR SpA’s Madrigal Pharmaceuticals MDGL Stock Holding History

Eurizon Capital SGR SpA’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Buy
538
+83
+18% +$42.5K ﹤0.01% 696
2026
Q1 		$231K Sell
455
-274
-38% -$131K ﹤0.01% 727
2025
Q4 		$425K Buy
+729
New +$372K ﹤0.01% 592

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Eurizon Capital SGR SpA's MDGL Position: Q2 2026 in Review

Eurizon Capital SGR SpA increased its Madrigal Pharmaceuticals (MDGL) stake by 18% in Q2 2026, buying an estimated $42.5K and bringing the position to 538 shares worth $285K. The position accounts for ﹤0.01% of the portfolio, ranked #696.

Eurizon Capital SGR SpA first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. The position peaked at $425K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Eurizon Capital SGR SpA held 538 shares of Madrigal Pharmaceuticals worth $285K as of Q2 2026.
  • Eurizon Capital SGR SpA bought 83 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $42.5K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #696 holding.
  • Eurizon Capital SGR SpA first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Eurizon Capital SGR SpA's Madrigal Pharmaceuticals position peaked at $425K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.